Comparing serotype coverage of pneumococcal vaccines with PCV21 (V116), a new 21-valent conjugate pneumococcal vaccine, and the epidemiology of its eight unique <i>Streptococcus pneumoniae</i> serotypes (15A, 15C, 16F, 23A, 23B, 24F, 31 and 35B) caus
V116 provided significantly (P < 0.05) greater coverage than PCV15, PCV20 and PPSV23 for adults, including older adults, across all Canadian geographic regions, and against IPD isolates with common antimicrobial resistance phenotypes, including MDR. The eight unique V116 serotypes accounted for a higher proportion of IPD isolate serotypes in patients aged ≥65 years than younger adults.
Authors
- Alyssa Golden (ORCID: https://orcid.org/0000-0002-1788-1794)
- Heather J. Adam (ORCID: https://orcid.org/0000-0002-5646-6454)
- Melanie R. Baxter
- Irene Martín (ORCID: https://orcid.org/0000-0002-3941-5583)
- James A. Karlowsky (ORCID: https://orcid.org/0000-0002-1939-464X)
- John J. Schellenberg (ORCID: https://orcid.org/0000-0003-3970-1608)
- George G. Zhanel (ORCID: https://orcid.org/0000-0002-3238-0082)
Institutions
- Public Health Agency of Canada (CA)
- University of Manitoba (CA)
Publication Details
- Journal
- Journal of Antimicrobial Chemotherapy
- Published
- 2025-03-25
- DOI
- https://doi.org/10.1093/jac/dkaf085
- Citations
- 8
- Primary Topic
- Pneumonia and Respiratory Infections
- Type
- article
- Field-Weighted Citation Impact
- 10.83
Funders
- University of Manitoba
- Public Health Agency of Canada
- Public Health Agency
- Merck Canada